References

1. VRAYLAR (cariprazine) [package insert]. Madison, NJ: Allergan USA, Inc.; 2019.

2. Data on file. Allergan.

3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM-5. 5th ed. American Psychiatric Association; 2013.

4. Awad AG, Rajagopalan K, Bolge SC, McDonnell DD. Prim Care Companion J Clin Psychiatry. 2007;9(3):195-202.

5. Manning JS. Prim Care Companion J Clin Psychiatry. 2005;7(6):259-267.

6. Perlis RH. Am J Manag Care. 2005;11(9 suppl):S271-S274.

7. Hirschfeld RM. J Affect Disord. 2014;169(suppl 1);S12-S16.

8. Hirschfeld RMA, Cass AR, Holt DCL, Carlson CA. J Am Board Fam Pract. 2005;18(4):233-239.

9. Hu J, Mansur R, McIntyre RS. Prim Care Companion CNS Disord. 2014;16(2).

10. Montgomery SA, Asberg M. Br J Psychiatry. 1979;134(4):382-389.

11. Young RC, Biggs JT, Ziegler VE, Meyer DA. Br J Psychiatry. 1978;133:429-435.

12. McIntyre RS, Soczynska JK, Cha DS, et al. J Affect Disord. 2015;172:259-264.

13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision. DSM-IV-TR. American Psychiatric Association; 2000.

14. Durgam S, Earley W, Lipschitz A, et al. Am J Psychiatry. 2016;173(3):271-281.

15. Earley W, Burgess MV, Rekeda L, et al. Am J Psychiatry. 2019;176(6):439-448.

16. Earley WR, Burgess MV, Khan B, et al. Bipolar Disord. 2020;22(4):372-384.

17. Data on file. Post-Hoc Analysis. Allergan.

18. Rosa AR, Sánchez-Moreno J, Martínez-Aran A, et al. Clin Pract Epidemiol Ment Health. 2007;3(5):1-8.

19. Calabrese JR, Keck PE Jr, Starace A, et al. J Clin Psychiatry. 2015;76(3):284-292.

20. Durgam S, Starace A, Li D, et al. Bipolar Disord. 2015;17(1):63-75.

21. Sachs GS, Greenberg WM, Starace A, et al. J Affect Disord. 2015;174:296-302.

22. Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S. Eur Neuropsychopharmacol. 2015;25(11):1882-1891.

23. Lieberman JA. CNS Drugs. 2004;18(4):251-267.

24. Stahl SM, Laredo S, Morrissette D. Ther Adv Psychopharmacol. 2020;10:1-11.

25. Durgam S, Starace A, Li D, et al. Schizophr Res. 2014;152(2-3):450-457.

26. Durgam S, Cutler AJ, Lu K, et al. J Clin Psychiatry. 2015;76(12):e1574-e1582.

27. Kane JM, Zukin S, Wang Y, et al. J Clin Psychopharmacol. 2015;35(4):367-373.

28. Durgam S, Earley W, Li R, et al. Schizophr Res. 2016;176(2-3):264-271.

29. Kay SR, Fiszbein A, Opler LA. Schizophr Bull. 1987;13(2):261-276.

  1. VRAYLAR (cariprazine) [package insert]. Madison, NJ: Allergan USA, Inc.; 2019.
  2. Data on file. Allergan.
  3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM-5. 5th ed. American Psychiatric Association; 2013.
  4. Awad AG, Rajagopalan K, Bolge SC, McDonnell DD. Prim Care Companion J Clin Psychiatry. 2007;9(3):195-202.
  5. Manning JS. Prim Care Companion J Clin Psychiatry. 2005;7(6):259-267.
  6. Perlis RH. Am J Manag Care. 2005;11(9 suppl):S271-S274.
  7. Hirschfeld RM. J Affect Disord. 2014;169(suppl 1);S12-S16.
  8. Hirschfeld RMA, Cass AR, Holt DCL, Carlson CA. J Am Board Fam Pract. 2005;18(4):233-239.
  9. Hu J, Mansur R, McIntyre RS. Prim Care Companion CNS Disord. 2014;16(2).
  10. Montgomery SA, Asberg M. Br J Psychiatry. 1979;134(4):382-389.
  11. Young RC, Biggs JT, Ziegler VE, Meyer DA. Br J Psychiatry. 1978;133:429-435.
  12. McIntyre RS, Soczynska JK, Cha DS, et al. J Affect Disord. 2015;172:259-264.
  13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision. DSM-IV-TR. American Psychiatric Association; 2000.
  14. Durgam S, Earley W, Lipschitz A, et al. Am J Psychiatry. 2016;173(3):271-281.
  15. Earley W, Burgess MV, Rekeda L, et al. Am J Psychiatry. 2019;176(6):439-448.
  16. Earley WR, Burgess MV, Khan B, et al. Bipolar Disord. 2020;22(4):372-384.
  17. Data on file. Post-Hoc Analysis. Allergan.
  18. Rosa AR, Sánchez-Moreno J, Martínez-Aran A, et al. Clin Pract Epidemiol Ment Health. 2007;3(5):1-8.
  19. Calabrese JR, Keck PE Jr, Starace A, et al. J Clin Psychiatry. 2015;76(3):284-292.
  20. Durgam S, Starace A, Li D, et al. Bipolar Disord. 2015;17(1):63-75.
  21. Sachs GS, Greenberg WM, Starace A, et al. J Affect Disord. 2015;174:296-302.
  22. Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S. Eur Neuropsychopharmacol. 2015;25(11):1882-1891.
  23. Lieberman JA. CNS Drugs. 2004;18(4):251-267.
  24. Stahl SM, Laredo S, Morrissette D. Ther Adv Psychopharmacol. 2020;10:1-11.
  25. Durgam S, Starace A, Li D, et al. Schizophr Res. 2014;152(2-3):450-457.
  26. Durgam S, Cutler AJ, Lu K, et al. J Clin Psychiatry. 2015;76(12):e1574-e1582.
  27. Kane JM, Zukin S, Wang Y, et al. J Clin Psychopharmacol. 2015;35(4):367-373.
  28. Durgam S, Earley W, Li R, et al. Schizophr Res. 2016;176(2-3):264-271.
  29. Kay SR, Fiszbein A, Opler LA. Schizophr Bull. 1987;13(2):261-276.